 The specific hypotheses to be tested are: when combined with growth hormone GH treatment, low dose transdermal estradiol LTE2 replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol VLTE2, which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. 